Placebo-Controlled Trials in the Management of Crohn’s Disease: An Umbrella Review of Meta-Analyses
Abstract
:1. Introduction
2. Methodology
2.1. Search Strategy
2.2. Eligibility Criteria
2.3. Quality Assessment
2.4. Data Extraction
3. Results
3.1. Identification and Description of the Studies
3.2. Quality Assessment
3.3. Effects and Adverse Events
3.3.1. Induction of Remission
Antimetabolites
Biologic Agents
- Anti-TNF agents
- Anti-IL-12/23p40 Antibodies
- Integrin Receptor Antagonists
Corticosteroids
3.3.2. Maintenance of Remission
Antimetabolites
Biologic Agents
- Anti-TNF Agents
- Anti-IL-12/23p40 Antibodies
- Integrin Receptor Antagonists
Corticosteroids
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kalla, R.; Ventham, N.T.; Satsangi, J.; Arnott, I.D. Crohn’s disease. BMJ 2014, 349, 1741–1755. [Google Scholar] [CrossRef] [PubMed]
- Reider, S.; Binder, L.; Fürst, S.; Hatzl, S.; Blesl, A. Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered? Cells 2022, 11, 3463. [Google Scholar] [CrossRef] [PubMed]
- Baumgart, D.C.; Sandborn, W.J. Crohn’s disease. Lancet 2012, 380, 1590–1605. [Google Scholar] [CrossRef] [PubMed]
- Lamb, C.A.; Kennedy, N.A.; Raine, T.; Hendy, P.A.; Smith, P.J.; Limdi, J.K.; Hayee, B.H.; Lomer, M.C.; Parkes, G.C.; Selinger, C.; et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019, 68 (Suppl. 3), s1–s106. [Google Scholar] [CrossRef]
- Canavan, C.; Abrams, K.R.; Mayberry, J. Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment. Pharmacol. Ther. 2006, 23, 1097–1104. [Google Scholar] [CrossRef]
- Lutgens, M.W.; Vleggaar, F.P.; Schipper, M.E.; Stokkers, P.C.; van der Woude, C.J.; Hommes, D.W.; de Jong, D.J.; Dijkstra, G.; van Bodegraven, A.A.; Oldenburg, B.; et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008, 57, 1246–1251. [Google Scholar] [CrossRef]
- Vavricka, S.R.; Brun, L.; Ballabeni, P.; Pittet, V.; Vavricka, B.M.P.; Zeitz, J.; Rogler, G.; Schoepfer, A.M.; Swiss IBD Cohort Study Group. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am. J. Gastroenterol. 2011, 106, 110–119. [Google Scholar] [CrossRef]
- Moja, L.; Danese, S.; Fiorino, G.; Del Giovane, C.; Bonovas, S. Systematic review with network meta-analysis: Comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn’s disease. Aliment. Pharmacol. Ther. 2015, 41, 1055–1065. [Google Scholar] [CrossRef]
- Juan, J.; Estiarte, R.; Colome, E.; Artes, M.; Jimenez, F.J.; Alonso, J. Burden of illness of Crohn’s disease in Spain. Dig. Liver Dis. 2003, 35, 853–861. [Google Scholar] [CrossRef]
- Engstrom, I. Inflammatory bowel disease in children and adolescents: Mental health and family functioning. J. Pediatr. Gastroenterol. Nutr. 1999, 28, S28–S33. [Google Scholar] [CrossRef]
- Loftus, E.V.; Jr Guerin, A.; Yu, A.P.; Wu, E.Q.; Yang, M.; Chao, J.; Mulani, P.M. Increased risks of developing anxiety and depression in young patients with Crohn’s disease. Am. J. Gastroenterol. 2011, 106, 1670–1677. [Google Scholar] [CrossRef] [PubMed]
- Goodhand, J.R.; Wahed, M.; Mawdsley, J.E.; Farmer, A.D.; Aziz, Q.; Rampton, D.S. Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm. Bowel Dis. 2012, 18, 2301–2309. [Google Scholar] [CrossRef]
- Graff, L.A.; Walker, J.R.; Lix, L.; Clara, I.; Rawsthorne, P.; Rogala, L.; Miller, N.; Jakul, L.; McPhail, C.; Ediger, J.; et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin. Gastroenterol. Hepatol. 2006, 4, 1491–1501. [Google Scholar] [CrossRef] [PubMed]
- Addolorato, G.I.O.V.A.N.N.I.; Mirijello, A.; D’Angelo, C.; Leggio, L.; Ferrulli, A.; Abenavoli, L.; Vonghia, L.; Cardone, S.; Leso, V.; Cossari, A.; et al. State and trait anxiety and depression in patients affected by gastrointestinal diseases: Psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. Int. J. Clin. Pract. 2008, 62, 1063–1069. [Google Scholar] [CrossRef]
- Bennebroek Evertsz’, F.; Thijssens, N.; Stokkers, P.; Grootenhuis, M.; Bockting, C.; Nieuwkerk, P.; Sprangers, M.A.G. Do inflammatory bowel disease patients with anxiety and depressive symptoms receive the care they need? J. Crohn’s Colitis 2012, 6, 68–76. [Google Scholar] [CrossRef] [PubMed]
- Yarani, R.; Shojaeian, A.; Palasca, O.; Doncheva, N.T.; Jensen, L.J.; Gorodkin, J.; Pociot, F. Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease. Front. Immunol. 2022, 13, 865777. [Google Scholar] [CrossRef]
- Wang, H.; Zhang, S.; Yu, Q.; Yang, G.; Guo, J.; Li, M.; Zeng, Z.; He, Y.; Chen, B.; Chen, M. Circulating microRNA223 is a new biomarker for inflammatory bowel disease. Medicine 2016, 95, e2703. [Google Scholar] [CrossRef]
- Kumar, A.; Cole, A.; Segal, J.; Smith, P.; Limdi, J.K. A review of the therapeutic management of Crohn’s disease. Therap. Adv. Gastroenterol. 2022, 15, 17562848221078456. [Google Scholar] [CrossRef]
- Kingsley, M.J.; Abreu, M.T. A Personalized Approach to Managing Inflammatory Bowel Disease. Gastroenterol. Hepatol. 2016, 12, 308–315. Available online: https://www.ncbi.nlm.nih.gov/pubmed/27499713 (accessed on 10 August 2023).
- Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210. [Google Scholar] [CrossRef]
- Feuerstein, J.D.; Ho, E.Y.; Shmidt, E.; Singh, H.; Falck-Ytter, Y.; Sultan, S.; Terdiman, J.P.; Sultan, S.; Cohen, B.L.; Chachu, K.; et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology 2021, 160, 2496–2508. [Google Scholar] [CrossRef] [PubMed]
- NIH NNHLBI. Quality Assessment Tool for Systematic Reviews and Meta-Analyses 2014. Available online: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools (accessed on 10 August 2023).
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [PubMed]
- Abbass, M.; Cepek, J.; Parker, C.E.; Nguyen, T.M.; MacDonald, J.K.; Feagan, B.G.; Khanna, R.; Jairath, V. Adalimumab for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2019, 2019, CD012878. [Google Scholar] [CrossRef]
- Yin, J.; Li, Y.; Chen, Y.; Wang, C.; Song, X. Adalimumab for induction of remission in patients with Crohn’s disease: A systematic review and meta-analysis. Eur. J. Med. Res. 2022, 27, 190. [Google Scholar] [CrossRef]
- Song, Y.N.; Zheng, P.; Xiao, J.H.; Lu, Z.J. Efficacy and safety of adalimumab for the Crohn’s disease: A systematic review and meta-analysis of published randomized placebo-controlled trials. Eur. J. Clin. Pharmacol. 2014, 70, 907–914. [Google Scholar] [CrossRef]
- Townsend, C.M.; Nguyen, T.M.; Cepek, J.; Abbass, M.; Parker, C.E.; MacDonald, J.K.; Khanna, R.; Jairath, V.; Feagan, B.G. Adalimumab for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2020, 5, Cd012877. [Google Scholar] [CrossRef]
- MacDonald, J.K.; Nguyen, T.M.; Khanna, R.; Timmer, A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2016, 11, Cd007572. [Google Scholar] [CrossRef]
- Davies, S.C.; Nguyen, T.M.; Parker, C.E.; MacDonald, J.K.; Jairath, V.; Khanna, R. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2019, 12, Cd012804. [Google Scholar] [CrossRef]
- Kawalec, P.; Moćko, P.; Malinowska-Lipien, I.; Brzostek, T. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn’s disease patients: A systematic review and meta-analysis. J. Comp. Eff. Res. 2017, 6, 601–612. [Google Scholar] [CrossRef]
- Yamazaki, H.; So, R.; Matsuoka, K.; Kobayashi, T.; Shinzaki, S.; Matsuura, M.; Okabayashi, S.; Kataoka, Y.; Tsujimoto, Y.; Furukawa, T.A.; et al. Certolizumab pegol for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2019, 8, Cd012893. [Google Scholar] [CrossRef]
- Okabayashi, S.; Yamazaki, H.; Yamamoto, R.; Anan, K.; Matsuoka, K.; Kobayashi, T.; Shinzaki, S.; Honzawa, Y.; Kataoka, Y.; Tsujimoto, Y.; et al. Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease. Cochrane Database Syst. Rev. 2022, 6, Cd013747. [Google Scholar] [CrossRef] [PubMed]
- McDonald, J.W.; Wang, Y.; Tsoulis, D.J.; MacDonald, J.K.; Feagan, B.G. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst. Rev. 2014, 2014, Cd003459. [Google Scholar] [CrossRef] [PubMed]
- Patel, V.; Wang, Y.; MacDonald, J.K.; McDonald, J.W.; Chande, N. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2014, 2014, Cd006884. [Google Scholar] [CrossRef]
- Chande, N.; Townsend, C.M.; Parker, C.E.; MacDonald, J.K. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2016, 10, Cd000545. [Google Scholar] [CrossRef]
- Hui, S.; Sinopoulou, V.; Gordon, M.; Aali, G.; Krishna, A.; Ding, N.S.; Boyapati, R.K. Vedolizumab for induction and maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2023, 7, Cd013611. [Google Scholar] [CrossRef]
- Chandar, A.K.; Singh, S.; Murad, M.H.; Peyrin-Biroulet, L.; Loftus, E.V., Jr. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn’s Disease: A Systematic Review and Meta-analysis. Inflamm. Bowel Dis. 2015, 21, 1695–1708. [Google Scholar] [CrossRef]
- Kuenzig, M.E.; Rezaie, A.; Seow, C.H.; Otley, A.R.; Steinhart, A.H.; Griffiths, A.M.; Kaplan, G.G.; Benchimol, E.I. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2014, 2014, Cd002913. [Google Scholar] [CrossRef]
- Rezaie, A.; Kuenzig, M.E.; Benchimol, E.I.; Griffiths, A.M.; Otley, A.R.; Steinhart, A.H. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2015, 2015, Cd000296. [Google Scholar] [CrossRef]
- Pierre, N.; Vieujean, S.; Peyrin-Biroulet, L.; Meuwis, M.A.; Louis, E. Defining Biological Remission in Crohn’s Disease: Interest, Challenges and Future Directions. J. Crohns Colitis. 2023, 17, 1698–1702. [Google Scholar] [CrossRef]
- Munshi, N.C.; Jagannath, S. Chapter 86—Plasma Cell Neoplasms. In Hematology, 7th ed.; Hoffman, R., Benz, E.J., Silberstein, L.E., Heslop, H.E., Weitz, J.I., Anastasi, J., Eds.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 1381–1418.e1. [Google Scholar]
- Scholar, E. Antimetabolites. In xPharm: The Comprehensive Pharmacology Reference; Enna, S.J., Bylund, D.B., Eds.; Elsevier: New York, NY, USA, 2007; pp. 1–4. [Google Scholar]
- Haskó, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 2008, 7, 759–770. [Google Scholar] [CrossRef]
- Mikhaylov, D.; Hashim, P.W.; Nektalova, T.; Goldenberg, G. Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. J. Clin. Aesthet. Dermatol. 2019, 12, 46–54. [Google Scholar] [PubMed]
- Tukukino, C.; Wallerstedt, S.M. Drug information centre queries and responses about drug interactions over 10 years-A descriptive analysis. Basic. Clin. Pharmacol. Toxicol. 2020, 126, 65–74. [Google Scholar] [CrossRef] [PubMed]
- Gearry, R.B.; Barclay, M.L. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2005, 20, 1149–1157. [Google Scholar] [CrossRef] [PubMed]
- Drugs.com. Mercaptopurine Drug Interactions 2024. Available online: https://www.drugs.com/drug-interactions/mercaptopurine-index.html (accessed on 13 November 2023).
- Crohn’s & Colitis UK. Biologics and Other Targeted Medicines 2023. Available online: https://crohnsandcolitis.org.uk/info-support/information-about-crohns-and-colitis/all-information-about-crohns-and-colitis/treatments/biologics-and-other-targeted-medicines (accessed on 26 January 2025).
- Reddy, S.P.; Lin, E.J.; Shah, V.V.; Wu, J.J. Chapter 10—Adalimumab. In Therapy for Severe Psoriasis; Wu, J.J., Feldman, S.R., Lebwohl, M.G., Eds.; Elsevier: Amsterdam, The Netherlands, 2016; pp. 111–126. [Google Scholar]
- Nesbitt, A.; Fossati, G.; Bergin, M.; Stephens, P.; Stephens, S.; Foulkes, R.; Brown, D.; Robinson, M.; Bourne, T. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis. 2007, 13, 1323–1332. [Google Scholar] [CrossRef]
- Kavanaugh, A.; Ritchlin, C.; Rahman, P.; Puig, L.; Gottlieb, A.B.; Li, S.; Wang, Y.; Noonan, L.; Brodmerkel, C.; Song, M.; et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 2014, 73, 1000. [Google Scholar] [CrossRef]
- Chen, L.; Ruan, G.; Cheng, Y.; Yi, A.; Chen, D.; Wei, Y. The role of Th17 cells in inflammatory bowel disease and the research progress. Front. Immunol. 2022, 13, 1055914. [Google Scholar] [CrossRef]
- Ueno, A.; Jeffery, L.; Kobayashi, T.; Hibi, T.; Ghosh, S.; Jijon, H. Th17 plasticity and its relevance to inflammatory bowel disease. J. Autoimmun. 2018, 87, 38–49. [Google Scholar] [CrossRef]
- Gubatan, J.; Keyashian, K.; Rubin, S.J.S.; Wang, J.; Buckman, C.A.; Sinha, S. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin. Exp. Gastroenterol. 2021, 14, 333–342. [Google Scholar] [CrossRef]
- De Lange, K.M.; Moutsianas, L.; Lee, J.C.; Lamb, C.A.; Luo, Y.; Kennedy, N.A.; Jostins, L.; Rice, D.L.; Gutierrez-Achury, J.; Ji, S.G.; et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 2017, 49, 256–261. [Google Scholar] [CrossRef]
- Rudick, R.A.; Sandrock, A. Natalizumab: Alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert. Rev. Neurother. 2004, 4, 571–580. [Google Scholar] [CrossRef]
- Soler, D.; Chapman, T.; Yang, L.L.; Wyant, T.; Egan, R.; Fedyk, E.R. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 2009, 330, 864–875. [Google Scholar] [CrossRef] [PubMed]
- Abdalla, M.I.; Herfarth, H. Budesonide for the treatment of ulcerative colitis. Expert. Opin. Pharmacother. 2016, 17, 1549–1559. [Google Scholar] [CrossRef] [PubMed]
- Tranchant, C.; Braun, S.; Warter, J.M. Mechanism of action of glucocorticoids: Role of lipocortins. Rev. Neurol. 1989, 145, 813–818. [Google Scholar]
- Arlt, W.; Allolio, B. Adrenal insufficiency. Lancet 2003, 361, 1881–1893. [Google Scholar] [CrossRef] [PubMed]
- Neary, N.; Nieman, L. Adrenal insufficiency: Etiology, diagnosis and treatment. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17, 217–223. [Google Scholar] [CrossRef]
Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | |
---|---|---|---|---|---|---|---|---|
McDonald et al. [33] | Yes | Yes | Yes | Yes | CD | Yes | NA | Yes |
Chande et al. [35] | Yes | Yes | Yes | Yes | NR | Yes | Yes | Yes |
Rezaie et al. [39] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
MacDonald et al. [28] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Kawalec et al. [30] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Yamazaki et al. [31] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Abbass et al. [24] | Yes | Yes | Yes | Yes | CD | Yes | NA | Yes |
Yin et al. [25] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Song et al. [26] | Yes | Yes | Yes | NR | NR | Yes | NA | Yes |
Chandar et al. [37] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Hui et al. [36] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Kuenzig et al. [38] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Patel et al. [34] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Davies et al. [29] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Townsend et al. [27] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Okabayashi et al. [32] | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes |
Intervention | Category | Nu. of RCTs | Nu. Placebo-Controlled RCTs | |
---|---|---|---|---|
McDonald et al. [33] | Methotrexate | Antimetabolites | 7 (495 patients) | 3 |
Chande et al. [35] | Purine analogues (Azathioprine, 6-mercaptopurine) | Antimetabolites | 13 (1211 patients) | 9 |
Song et al. [26] | Anti-TNF agent Adalimumab | Biologic agents | 6 (1676 patients) | 4 |
Abbass et al. [24] | Anti-TNF agent Adalimumab | Biologic agents | 3 (714 patients) | 3 |
Yin et al. [25] | Anti-TNF agent Adalimumab | Biologic agents | 4 (919 patients) | 4 |
Yamazaki et al. [31] | Anti-TNF agent Certolizumab pegol | Biologic agents | 4 (1485 patients) | 4 |
MacDonald et al. [28] | Anti-IL-12/23p40 antibodies (Briakinumab or Ustekinumab) | Biologic agents | 6 (2324 patients) | 6 |
Kawalec et al. [30] | Anti-IL-12/23p40 antibodies Ustekinumab | Biologic agents | 3 (not reported) | 2 |
Chandar et al. [37] | Anti-α4-integrins (Natalizumab and Vedolizumab) | Biologic agents | 8 (2672 patients) | 8 |
Hui et al. [36] | Anti-α4-integrins Vedolizumab | Biologic agents | 5 (2020 patients) | 4 |
Rezaie et al. [39] | Budesonide | Corticosteroids | 14 (1805 patients) | 3 |
Intervention | Category | Nu. of RCTs | Nu. Placebo-Controlled RCTs | |
---|---|---|---|---|
Patel et al. [34] | Methotrexate | Antimetabolites | 5 (333 patients) | 2 |
Song et al. [26] | Anti-TNF agent (Adalimumab) | Biologic agents | 6 (1676 patients) | 6 |
Townsend et al. [27] | Anti-TNF agent (Adalimumab) | Biologic agents | 6 (1158 patients) | 4 |
Okabayashi et al. [32] | Anti-TNF agent (Certolizumab pegol) | Biologic agents | 1 (428 patients) | 1 |
Davies et al. [29] | Anti-IL-12/23p40 antibodies (Briakinumab or Ustekinumab) | Biologic agents | 3 (646 patients) | 3 |
Chandar et al. [37] | Anti-α4-integrins (Natalizumab and Vedolizumab) | Biologic agents | 8 (2672 patients) | 2 |
Hui et al. [36] | Anti-α4-integrins (Vedolizumab) | Biologic agents | 5 (2020 patients) | 3 |
Kuenzig et al. [38] | Budesonide | Corticosteroids | 12 (1273 patients) | 8 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Silva, R.; Azevedo, J.N.d.; Machado, J.P.; Rodrigues, J.M. Placebo-Controlled Trials in the Management of Crohn’s Disease: An Umbrella Review of Meta-Analyses. Med. Sci. 2025, 13, 12. https://doi.org/10.3390/medsci13010012
Silva R, Azevedo JNd, Machado JP, Rodrigues JM. Placebo-Controlled Trials in the Management of Crohn’s Disease: An Umbrella Review of Meta-Analyses. Medical Sciences. 2025; 13(1):12. https://doi.org/10.3390/medsci13010012
Chicago/Turabian StyleSilva, Richard, José Nunes de Azevedo, Jorge Pereira Machado, and Jorge Magalhães Rodrigues. 2025. "Placebo-Controlled Trials in the Management of Crohn’s Disease: An Umbrella Review of Meta-Analyses" Medical Sciences 13, no. 1: 12. https://doi.org/10.3390/medsci13010012
APA StyleSilva, R., Azevedo, J. N. d., Machado, J. P., & Rodrigues, J. M. (2025). Placebo-Controlled Trials in the Management of Crohn’s Disease: An Umbrella Review of Meta-Analyses. Medical Sciences, 13(1), 12. https://doi.org/10.3390/medsci13010012